NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review

Genetics in Medicine

Volumn 4, Issue 2, 2002, Pages 62-70

  Nebert, Daniel W ^a   Roe, Amy L ^b   Vandale, Susan E ^a   Bingham, Eula ^a   Oakley, Gregory G ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Benzene exposure; Benzene metabolism; CYP2E1; Myelodysplastic syndrome; NAD(P)H:Quinone oxidoreductase (NQO1) gene polymorphism; Therapy related acute myeloid leukemia

Indexed keywords

BENZENE; CYTOCHROME P450 2E1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; MYELOPEROXIDASE; OXIDOREDUCTASE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ALLELE; APLASTIC ANEMIA; BONE MARROW TOXICITY; CANCER RISK; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ETHNOLOGY; GENE FREQUENCY; GENE MUTATION; GENETIC CODE; HOMOZYGOTE; HUMAN; LEUKEMIA; NONHUMAN; POPULATION GENETICS; PROTEIN FOLDING; REPORTER GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BONE MARROW DISEASE; CHEMICALLY INDUCED DISORDER; ENVIRONMENTAL EXPOSURE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; POINT MUTATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANIMALIA;

ALLELES; ANIMALS; BENZENE; BONE MARROW DISEASES; ENVIRONMENTAL EXPOSURE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0036518402     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200203000-00003     Document Type: Review

References (59)

1. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204.
2. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H. quinone oxidoreductase-1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77-97.
3. Neben DW; Petersen DD, Fornace AJ Jr. Cellular responses to oxidative stress: the [Ah] gene battery as a paradigm. Environ Health Perspect 1990;88:13-25.
4. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999;39:67-101.
5. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000;59:65-85.
6. Jaiswal AK, McBride OW, Adesnik M, Nebert DW. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J Biol Chem 1988;263:13572-13578.
7. Jaiswal AK, Bell DW, Radjendirane V, Testa JR. Localization of human NQO1 gene to chromosome 16q22 and NQO2 to 6p25 and associated polymorphisms. Pharmacogenetics 1999;9:413-418.
8. Long DJ II, Jaiswal AK. NRH. quinone oxidoreductase-2 (NQO2). Chem Biol Interact 2000;129:99-112.
9. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin C sensitivity. Cancer Res 1992;52:797-802.
10. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, Wang M, Xu X, Lee BK, Schwartz BS, Wiencke JK. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer 1997;76:852-854.
11. Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics 2001;1:19-22.
12. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998;273:7382-7389.
13. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol 1996;60(suppl 1):111-118.
14. Oppermann UC, Maser E. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 2000;144:71-81.
15. 5, microsomal epoxide hydrolase, and glutathione transferases: evidence for an important role of microsomal epoxide hydrolase in the formation of hydroquinone. Toxicol Appl Pharmacol 1993;122:172-181.
16. Nakagawa M, Matsuura K, Hara A, Sawada H, Bunai Y, Ohya I. Dimeric dihydrodiol dehydrogenase in monkey kidney. Substrate specificity, stereospecificity of hydrogen transfer, and distribution. J Biochem (Tokyo) 1989;106:1104-1109.
17. Shinagawa Y. Molecular orbital studies on the structure-activity relationships of catechol O-methyltransferase inhibitors. Jpn J Pharmacol 1992;58:95-106.
18. Snyder R, Kalf GF. A perspective on benzene leukemogenesis. Crit Rev Toxicol 1994; 24:177-209.
19. Smith MT. Overview of benzene-induced aplastic anaemia. Eur J Haematol 1996; 60(suppl 1):107-110.
20. Smith MT. Mechanistic studies of benzene toxicity-implications for risk assessment. Adv Exp Med Biol 1996;387:259-266.
21. Smith MT. The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia. Environ Health Perspect 1996;104(suppl 6):1219-1225.
22. Snyder R, Hedli CC. An overview of benzene metabolism. Environ Health Perspea 1996;104(suppl 6):1165-1171.
23. Rothman N, Smith MT, Hayes RB, Li GL, Irons RD, Dosemeci M, Haas R, Stillman WS, Linet M, Xi LQ, Bechtold WE, Wiemels J, Campleman S, Zhang L, Quintana PJ, Titenko-Holland N, Wang YZ, Lu W, Kolachana P, Meyer KB, Yin S. An epidemiologic study of early biologic effects of benzene in Chinese workers. Environ Health Perspect 1996;104(suppl 6):1365-1370.
24. Williams JA. Single-nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 2001;22:209-214.
25. Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 1998;154:47-85.
26. Strange RC, Fryer AA. Chapter 19. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ 1999;148:231-249.
27. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000;151:7-32.
28. Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett 2000;112-113:365-370.
29. Nebert DW, Ingelman-Sundberg M, Daly AK. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev 1999;31:467-487.
30. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione S-transferase '2-1 (GSTT1) gene defect. Lancet 1996;347:295-297.
31. Preudhomme C, Nisse C, Hebbar M, Vanrumbeke M, Brizard A, Lai JL, Fenaux P. Glutathione S-transferase'12-1 (GSTT1) gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia 1997;11:1580-1582.
32. Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, Park BK. Increased resistance to acetaminophen hepatotoxicity in mice lacking the Gstp genes. Proc Natl Acad Sci USA 2000;97:12741-12745.
33. Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, Li GL, Dosemeci M, Linet M, Zhang L, Xi L, Wacholder S, Lu W, Meyer KB, Titenko-Holland N, Stewart JT, Yin S, Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C>T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997;57:2839-2842.
34. Gonzalez FJ, Kimura S. Understanding the role of xenobiotic metabolism in chemical carcinogenesis using gene knockout mice. Mutat Res 2001;477:79-87.
35. Oscarson M, Ingelman-Sundberg M, Daly AK, Nebert DW. Human cytochrome P450 (CYP) alleles [web site]. 2001; http://www.imm.ki.se/CYPalleles/
36. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Drager BJ, Sies H. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-239.
37. Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H. Predisposition towards urolithiasis associated with the NQO1 null allele. Pharmacogenetics 1998;8: 453-454.
38. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10:279-290.
39. Clairmont A, Sies H, Ramachandran S, Lear JT, Smith AG, Bowers B, Jones PW, Fryer AA, Strange RC. Association of the NAD(P)H:quinone oxidoreductase (NQO1) null allele with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999;20:1235-1240.
40. Siegel D, Ryder J, Ross D. NAD(P)H:quinone oxidoreductase-1 expression in human bone marrow endothelial cells. Toxicol Lett 2001;125:93-98.
41. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, Roman E, Roddam P, Cartwright R, Morgan G. Low NAD(P)H. quinone oxidoreductase-1 activity is associated with increased risk of acute leukemia in adults. Blood 2001;97:1422-1426.
42. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6: 87-92.
43. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. Genetic polymorphisms of NAD-(P)H:quinone oxidoreductase, CYPIA1, and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 2001;33:133-141.
44. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ, Christiani DC. The NAD(P)H. quinone oxidoreductase-1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001;10:303-309.
45. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. Polymorphisms in the NAD(P)H:quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001;34:177-183.
46. Shao M, Liu Z, Tao E, Chen B. Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001;18:l22-124.
47. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase-1 and -2. Biochem Biophys Res Commun 2001;288:887-892.
48. Peters ES, Kelsey KT, Wiencke JK, Park S, Chen P, Miike R, Wrensch MR. NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiol Biomarkers Prev 2001;10:151-152.
49. Phillips RM, Burger AM, Fiebig HH, Double JA. Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity, and the response of xenografts to mitomycin C chemotherapy in vivo. Biochem Pharmacol 2001;62:1371-1377.
50. Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D. Relationship between NAD(P)H:quinone oxidoreductase-1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001;61:1509-1516.
51. Turker A, Guler N. Therapy-related acute myeloid leukemia after exposure to 5-fluorouracil: a case report. Hematol Cell Ther 1999;41:195-196.
52. Kollmannsberger C, Kuzcyk M, Mayer F, Hartmann JT, Kanz L, Bokemeyer C. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999;17: 275-281.
53. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999;84:937-945.
54. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT. Prevalence of the inactivating 609C>T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803-807.
55. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Dike N, Ino T, Utsunomiya A, Maruta A, Jin-nai I, Kamada N, Kubota Y, Nakamura H, Shimazaki C, Horiike S, Kodera Y, Saito H, Ueda R, Wiemels J, Ohno R. Analysis of genetic polymorphisms in NQO1, GSTM1, GSTT1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000;6:4091-4095.
56. Iida A, Sekine A, Saito S, Kitamura Y, Kitamoto T, Osawa S, Mishima C, Nakamura Y. Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J Hum Genet 2001;46:225-240.
57. Le Marchand L, Lum-Jones A, Saltzman B, Visaya V, Nomura AM, Kolonel LN. Feasibility of collecting buccal cell DNA by mail in a cohort study. Cancer Epidemiol Biomarkers Prev 2001;10:701-703.
58. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase-1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 1999;96:8150-8155.
59. Nebert DW, Bingham E. Pharmacogenomics: out of the lab and into the community. Trends Biotechnol 2001;19:479-483.